Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial
Olivier Mir1, Thomas Brodowicz2, Antoine Italiano3, Jennifer Wallet4, Jean-Yves Blay5, François Bertucci6, Christine Chevreau7, Sophie Piperno-Neumann8, Emmanuelle Bompas9, Sébastien Salas10, Christophe Perrin11, Corinne Delcambre12, Bernadette Liegl-Atzwanger13, Maud Toulmonde3, Sarah Dumont1, Isabelle Ray-Coquard5, Stéphanie Clisant14, Sophie Taieb15, Cécile Guillemet16, Maria Rios17
1Medical Oncology Department, Gustave Roussy, Villejuif, France
2Medical University Vienna, General Hospital, Vienna, Austria
3Medical Oncology Department, Institut Bergonié, Bordeaux, France
4Biostatisitics and Methodology Unit, Centre Oscar Lambret, Lille, France
5Medical Oncology Department, Centre Léon Bérard, Lyon, France
6Medical Oncology Department, Institut Paoli-Calmette, Marseille, France
7Medical Oncology Department, Institut Universitaire de Cancérologie de Toulouse, Oncopôle, Toulouse, France
8Medical Oncology Department, Institut Curie, Paris, France
9Medical Oncology Department, René Gauducheau, Saint-Herblain, France
10Medical Oncology Department, CH La Timone, Marseille, France
11Medical Oncology Department, Centre Eugène Marquis, Rennes, France
12Medical Oncology Department, Centre François Baclesse, Caen, France
13Institute of Pathology, Medical University of Graz, Graz, Austria
14Clinical Resarch Unit, Centre Oscar Lambret and Methodology and Clinical Research Platform of SIRIC OncoLille, Lille, France
15Radiology Department, Centre Oscar Lambret, Lille, France
16Medical Oncology Department, Centre Henri Becquerel, Rouen France
17Medical Oncology Department, Centre Alexis Vautrin, Nancy, France
Thông tin
Thông tin xuất bản
The Lancet Oncology
Tập 17
1732-1742
Thông tin tác giả